Athira Pharma, Inc. (ATHA) 10-Year Financial Performance & Capital Metrics

ATHA • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

AboutAthira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.Show more

Revenue $0
EBITDA -$100M +19.7%
Net Income -$97M +17.6%
EPS (Diluted) -25.20 +18.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -110.77% -71.9%
ROIC -389.99% -277.7%
Debt/Equity 0.03 +122.9%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 92 (top 8%)
✓Trading at only 0.5x book value

✗Weaknesses

✗Weak Piotroski F-Score: 0/9
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM65.46%

EPS CAGR

10Y-

5Y-

3Y-

TTM66.22%

ROCE

10Y Avg-82.37%

5Y Avg-51.05%

3Y Avg-73.11%

Latest-113.98%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	2M	479K	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-
Gross Profit+	0	0	-2M	-479K	0	0	0
Gross Margin %	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	0.76%	1%	-	-
Operating Expenses+	5.01M	4.7M	18M	63.54M	104.02M	125.47M	100.9M
OpEx % of Revenue	-	-	-	-	-	-	-
Selling, General & Admin	1.42M	1.66M	6.71M	21.23M	32.55M	33.3M	26.09M
SG&A % of Revenue	-	-	-	-	-	-	-
Research & Development	3.59M	3.79M	13.29M	42.79M	61.46M	93.79M	70.68M
R&D % of Revenue	-	-	-	-	-	-	-
Other Operating Expenses	0	-754K	-2M	-479K	10M	-1.63M	4.13M
Operating Income+	-5.01M	-5.45M	-20M	-64.02M	-104.02M	-125.47M	-100.9M
Operating Margin %	-	-	-	-	-	-	-
Operating Income Growth %	-	-0.09%	-2.67%	-2.2%	-0.62%	-0.21%	0.2%
EBITDA+	0	-5.45M	-19.99M	-63.54M	-103.17M	-124.5M	-99.93M
EBITDA Margin %	-	-	-	-	-	-	-
EBITDA Growth %	-	-	-2.67%	-2.18%	-0.62%	-0.21%	0.2%
D&A (Non-Cash Add-back)	5.01M	2K	2K	479K	845K	969K	970K
EBIT	-5.09M	-4.82M	-19.59M	-54.85M	-88.86M	-126.94M	-96.78M
Net Interest Income+	76K	-295K	-243K	334K	-21.1M	7.64M	3.96M
Interest Income	85K	51K	124K	337K	3.22M	7.64M	3.96M
Interest Expense	9K	346K	367K	3K	24.32M	0	0
Other Income/Expense	-88K	288K	40K	9.17M	8.38M	7.79M	3.96M
Pretax Income+	-5.1M	-5.16M	-19.95M	-54.85M	-95.64M	-117.67M	-96.94M
Pretax Margin %	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%
Net Income+	-5.1M	-5.16M	-19.95M	-54.85M	-95.64M	-117.67M	-96.94M
Net Margin %	-	-	-	-	-	-	-
Net Income Growth %	-	-0.01%	-2.87%	-1.75%	-0.74%	-0.23%	0.18%
Net Income (Continuing)	-5.1M	-5.16M	-19.95M	-54.85M	-95.64M	-117.67M	-96.94M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-1.60	-1.40	-6.10	-14.90	-25.30	-30.90	-25.20
EPS Growth %	-	0.13%	-3.36%	-1.44%	-0.7%	-0.22%	0.18%
EPS (Basic)	-1.60	-1.40	-6.10	-14.90	-25.30	-30.90	-25.20
Diluted Shares Outstanding	3.26M	3.26M	3.25M	3.69M	3.77M	3.8M	3.85M
Basic Shares Outstanding	3.26M	3.26M	3.25M	3.69M	3.77M	3.8M	3.85M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	4.9M	2.16M	192.34M	260.8M	207.53M	154.73M	54.84M
Cash & Short-Term Investments	4.82M	2.06M	184.68M	253.76M	200.34M	147.42M	51.27M
Cash Only	3.32M	2.06M	60.63M	110.54M	95.97M	90.58M	48.44M
Short-Term Investments	1.5M	0	124.06M	143.22M	104.38M	56.84M	2.84M
Accounts Receivable	6K	7K	1.3M	2.34M	1.23M	1.63M	0
Days Sales Outstanding	-	-	-	-	-	-	-
Inventory	0	0	0	0	-1.23M	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	7.19M	5.68M	3.57M
Total Non-Current Assets+	36K	29K	87.23M	71.21M	50.62M	5.52M	3.94M
Property, Plant & Equipment	0	0	3.58M	5.22M	5.32M	4.44M	3.25M
Fixed Asset Turnover	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	36K	0	83.51M	65.94M	44.83M	631K	631K
Other Non-Current Assets	0	29K	132K	56K	475K	448K	55K
Total Assets+	4.93M	2.19M	279.56M	332.01M	258.15M	160.25M	58.78M
Asset Turnover	-	-	-	-	-	-	-
Asset Growth %	-	-0.56%	126.71%	0.19%	-0.22%	-0.38%	-0.63%
Total Current Liabilities+	572K	1.27M	4.41M	9.29M	21.43M	28.84M	13.13M
Accounts Payable	121K	421K	1.16M	567K	2.5M	129K	319K
Days Payables Outstanding	-	-	211.34	432.06	-	-	-
Short-Term Debt	0	0	0	0	0	0	414K
Deferred Revenue (Current)	0	0	0	0	0	0	0
Other Current Liabilities	0	230K	1.62M	1.91M	15.19M	23.8M	12.4M
Current Ratio	8.56x	1.70x	43.66x	28.07x	9.68x	5.37x	4.18x
Quick Ratio	8.56x	1.70x	43.66x	28.07x	9.74x	5.37x	4.18x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	19.25M	20.64M	876K	1.63M	1.58M	1.22M	803K
Long-Term Debt	722K	1.55M	0	0	0	0	0
Capital Lease Obligations	0	0	876K	1.63M	1.58M	1.22M	803K
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	18.53M	19.09M	0	0	0	0	0
Total Liabilities	19.82M	21.91M	5.28M	10.92M	23.02M	30.06M	13.94M
Total Debt+	722K	1.55M	1M	1.92M	1.91M	1.58M	1.22M
Net Debt	-2.6M	-503K	-59.63M	-108.62M	-94.06M	-89M	-47.22M
Debt / Equity	-	-	0.00x	0.01x	0.01x	0.01x	0.03x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-556.56x	-15.75x	-54.48x	-21340.67x	-4.28x	-	-
Total Equity+	-14.89M	-19.72M	274.28M	321.08M	235.14M	130.19M	44.84M
Equity Growth %	-	-0.32%	14.91%	0.17%	-0.27%	-0.45%	-0.66%
Book Value per Share	-4.56	-6.05	84.43	86.96	62.32	34.24	11.65
Total Shareholders' Equity	-14.89M	-19.72M	274.28M	321.08M	235.14M	130.19M	44.84M
Common Stock	3K	0	3K	4K	4K	4K	4K
Retained Earnings	-15.93M	-21.09M	-41.04M	-95.89M	-191.53M	-309.21M	-406.15M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	-17.05M	0	33K	-388K	-1.96M	-349K	1K
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.48M	-3.71M	-24.11M	-43.1M	-72.47M	-100.75M	-97.17M
Operating CF Margin %	-	-	-	-	-	-	-
Operating CF Growth %	-	0.17%	-5.49%	-0.79%	-0.68%	-0.39%	0.04%
Net Income	-5.1M	-5.16M	-19.95M	-54.85M	-95.64M	-117.67M	-96.94M
Depreciation & Amortization	0	0	251K	479K	1.05M	969K	455K
Stock-Based Compensation	196K	0	633K	4.62M	0	10.62M	11.05M
Deferred Taxes	0	0	-251K	0	0	0	0
Other Non-Cash Items	173K	770K	1.65M	648K	10.18M	-1.2M	248K
Working Capital Changes	245K	678K	-6.45M	6M	11.94M	6.53M	-11.98M
Change in Receivables	0	0	-1.3K	-1.04M	1.11M	-401K	1.63M
Change in Inventory	0	0	1.3K	0	0	0	0
Change in Payables	291K	701K	2.6M	5.15M	2.1M	7.37M	-5.75M
Cash from Investing+	2.01M	1.51M	-210.07M	-4.08M	57.66M	95.09M	54.83M
Capital Expenditures	0	0	-2.32M	-1.57M	-1.14M	-304K	-33K
CapEx % of Revenue	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	7K	6K	36K	0	0	0	0
Cash from Financing+	1.46M	946K	292.75M	97.09M	654K	493K	194K
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	98K	0	643K	327K	0	0	0
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-4.48M	-3.71M	-26.43M	-44.67M	-73.61M	-101.06M	-97.2M
FCF Margin %	-	-	-	-	-	-	-
FCF Growth %	-	0.17%	-6.12%	-0.69%	-0.65%	-0.37%	0.04%
FCF per Share	-1.37	-1.14	-8.14	-12.10	-19.51	-26.58	-25.26
FCF Conversion (FCF/Net Income)	0.88x	0.72x	1.21x	0.79x	0.76x	0.86x	1.00x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-15.68%	-18.43%	-34.39%	-64.42%	-110.77%
Return on Invested Capital (ROIC)	-	-	-15.43%	-22.48%	-44.13%	-103.25%	-389.99%
Debt / Equity	-	-	0.00x	0.01x	0.01x	0.01x	0.03x
Interest Coverage	-556.56x	-15.75x	-54.48x	-21340.67x	-4.28x	-	-
FCF Conversion	0.88x	0.72x	1.21x	0.79x	0.76x	0.86x	1.00x

Frequently Asked Questions

Growth & Financials

Athira Pharma, Inc. (ATHA) grew revenue by 0.0% over the past year. Growth has been modest.

Athira Pharma, Inc. (ATHA) reported a net loss of $37.7M for fiscal year 2024.

Dividend & Returns

Athira Pharma, Inc. (ATHA) has a return on equity (ROE) of -110.8%. Negative ROE indicates the company is unprofitable.

Athira Pharma, Inc. (ATHA) had negative free cash flow of $52.3M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener